<DOC>
	<DOCNO>NCT00283959</DOCNO>
	<brief_summary>The purpose study collect information safety AT1001 ( migalastat hydrochloride ) AT1001 work patient Fabry disease .</brief_summary>
	<brief_title>A 12-Week Safety Pharmacodynamic Study AT1001 Patients With Fabry Disease</brief_title>
	<detailed_description>The purpose study determine effect AT1001 give orally patient Fabry disease . Patients visit clinic 4 week prior dose determine eligibility study , return second visit baseline safety assessment , include skin , cardiac , renal biopsy . Patients receive oral dos AT1001 12 week visit clinic 3 time , every 4 week , evaluation test . Skin , cardiac , renal biopsy , functional assessment perform end 12 week period . Patients may give opportunity enter study extension phase additional 36 week , require three clinic visit , final set functional test biopsy . All study participant final follow visit 2 week end study .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Males 18 65 year age ( inclusive ) Hemizygous Fabry disease Have confirm diagnosis Fabry disease document missense gene mutation ( individual familial ) Have enhanceable enzyme activity base vitro test Have document evidence cardiac and/or renal dysfunction ( e.g. , abnormal ECG , leave ventricular hypertrophy , renal insufficiency ) Must previously untreated ERT substrate depletion Fabry disease willing undergo two kidney , two cardiac , three skin biopsy Agree sexually abstinent use condom spermicide engage sexual activity course study period 30 day follow completion study Willing able sign inform consent form History significant disease Fabry disease History organ transplant Serum creatinine great 1.5 mg/dL Day 2 Screening 12lead ECG demonstrate QTc &gt; 450 msec prior dose Pacemaker contraindication MRI scan Taking medication prohibit protocol : Fabrazyme ( agalsidase beta ) , Replagal ( agalsidase alfa ) , Glyset ( miglitol ) , Zavesca ( miglustat ) , experimental therapy indication Participated clinical trial last 30 day Any condition , , opinion investigator , would jeopardize safety patient impact validity study result</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>